# Bio-Techne Corp (TECH) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $72.43, market value $11.4 billion.

## Valuation
- **P/E (trailing): 62.4×** (5-yr avg 67.3×, 3-yr avg 79.9×). Bio-Techne Corp trades at 62.4× trailing earnings, close to its own five-year average of 67.3×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 31.4×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.21**. A PEG of 0.21 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 9.3×**. Each dollar of revenue is priced at 9.3×.
- **Price / book: 5.4×**. The shares trade at 5.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 32.3×**. Enterprise value is 32.3× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.3%** (5-yr avg 2.3%). Free cash flow equals 2.3% of the market value, in line with its five-year average of 2.3%.
- **Earnings yield: 1.6%**. The inverse of the P/E: 1.6% of the price is earned each year.

## Profitability
- **Gross margin: 65.8%**. Bio-Techne Corp keeps 65.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 20.7%**. 20.7% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 15.0%**. 15.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 8.6%**. 8.6% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 9.7%**. Return on all capital, debt included, is 9.7%.
- **Return on assets: 7.0%**. Each dollar of assets produces 7.0% of profit.

## Growth
- **Revenue growth (1 yr): -0.4%** (3-yr 2.2%/yr, 5-yr 5.5%/yr). Revenue fell 0.4% over the last year, against 5.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 152.2%** (3-yr -13.0%/yr, 5-yr 5.9%/yr). Earnings per share rose 152.2%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 6.8%/yr**. Free cash flow has compounded at 6.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.09**. Debt is 0.09 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Bio-Techne Corp holds more cash than debt.
- **Current ratio: 4.55** (quick 4.55). Current assets cover the next year's liabilities 4.55 times.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.44%** ($0.32 per share, trailing). Bio-Techne Corp yields 0.44%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 27%** (19% of free cash flow). 27% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 18**. 18 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 0.0%/yr** (1-yr 0.0%). The dividend has not grown over five years.

## Analyst view
- **Analyst consensus: hold** (11 analysts). 11 analysts cover Bio-Techne Corp; the consensus is hold, with an average price target of $70.73 (-2% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 37.5%** (YTD 23.6%, 3-mo 39.3%). The shares are up 37.5% over twelve months including dividends.
- **From 52-week high: -0.3%** (67.7% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 65**. An RSI of 65 is neutral.
- **Beta (1 yr): 0.87** (volatility 47%). Beta of 0.87 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TECH · Page: https://foliofundamentals.com/stocks/tech

Not investment advice.